We are live on ! Find out more
ARIA

Ariad Pharmaceuticals Inc
ARIA

Delisted

ARIA was delisted on the 15th of February, 2017.

169 hedge funds and large institutions have $790M invested in Ariad Pharmaceuticals Inc in 2014 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 63 increasing their positions, 44 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 44

19% more call options, than puts

Call options by funds: $31.5M | Put options by funds: $26.5M

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

7% less first-time investments, than exits

New positions opened: 27 | Existing positions closed: 29

1% less funds holding

Funds holding: 171169 (-2)

10% less capital invested

Capital invested by funds: $877M → $790M (-$86.6M)

Holders
169
Holders Change
-2
Holders Change %
-1.17%
% of All Funds
4.86%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.11%
New
27
Increased
63
Reduced
44
Closed
29
Calls
$31.5M
Puts
$26.5M
Net Calls
+$5.02M
Net Calls Change
+$1.41M
Name Holding Trade Value Shares
Change
Change in
Stake
T. Rowe Price Associates
101
T. Rowe Price Associates
Maryland
$303K
Prudential Financial
102
Prudential Financial
New Jersey
$285K +$205K +29,800 +200%
CWM
103
Concert Wealth Management
California
$264K -$5.85K -851 -2%
HW
104
Hancock Whitney
Mississippi
$255K
QT
105
Quantbot Technologies
New York
$241K +$261K +37,910 New
Public Employees Retirement Association of Colorado
106
Public Employees Retirement Association of Colorado
Colorado
$225K -$42.2K -6,140 -15%
LPL Financial
107
LPL Financial
California
$218K -$15.3K -2,231 -6%
Principal Financial Group
108
Principal Financial Group
Iowa
$218K +$236K +34,263 New
SCM
109
Stevens Capital Management
Pennsylvania
$202K +$218K +31,649 New
N
110
Natixis
France
$191K -$299K -43,450 -59%
CAM
111
Congress Asset Management
Massachusetts
$191K
AG
112
Aperio Group
California
$179K -$57.6K -8,375 -23%
Verition Fund Management
113
Verition Fund Management
Connecticut
$179K +$193K +28,081 New
HSBC Holdings
114
HSBC Holdings
United Kingdom
$172K -$39.2K -5,696 -17%
DCM
115
Dynamic Capital Management
Jersey
$171K +$51.6K +7,500 +39%
LA
116
Linden Advisors
New York
$170K +$184K +26,800 New
PA
117
Profund Advisors
Maryland
$167K +$89.3K +12,978 +98%
Parallax Volatility Advisers
118
Parallax Volatility Advisers
California
$164K -$26.9K -3,908 -13%
Bank of Montreal
119
Bank of Montreal
Ontario, Canada
$164K
Jane Street
120
Jane Street
New York
$155K -$627K -91,183 -79%
WFM
121
Wilmington Funds Management
Delaware
$133K +$144K +20,940 New
VAM
122
Visium Asset Management
New York
$124K +$134K +19,450 New
William Blair & Company
123
William Blair & Company
Illinois
$118K +$129K +18,705 New
Credit Agricole
124
Credit Agricole
France
$114K -$58.2K -8,461 -32%
AB
125
Amalgamated Bank
New York
$102K -$32.7K -4,752 -23%

ARIA Hedge Fund Activity: Q2 2014 in Review

169 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Ariad Pharmaceuticals Inc (ARIA) for Q2 2014, worth a combined $790M — down 9.9% from $877M a quarter earlier.

Sellers outnumbered buyers: 29 funds closed out of ARIA and 27 opened new positions — a net loss of 2 holders — while 44 trimmed existing stakes and 63 added.

The largest buyer was AQR Capital Management, adding an estimated $20.4M. The largest seller was Slate Path Capital, exiting entirely with an estimated $53.4M sold.

  • 169 institutional investors held Ariad Pharmaceuticals Inc (ARIA) as of Q2 2014, down from 171 in Q1 2014.
  • Funds reported $790M of Ariad Pharmaceuticals Inc stock for Q2 2014, down 9.9% quarter-over-quarter.
  • 27 funds opened new Ariad Pharmaceuticals Inc positions in Q2 2014 and 29 closed out, a net change of -2 holders.
  • The largest Ariad Pharmaceuticals Inc buyer in Q2 2014 was AQR Capital Management, an estimated $20.4M added.
  • The largest Ariad Pharmaceuticals Inc seller in Q2 2014 was Slate Path Capital, an estimated $53.4M sold.

Based on aggregated 13F filings for Q2 2014.